STOCKS TELEGRAPH

Tag: Edgewise Therapeutics

  • 3 Stocks to Keep Watching Closely: Cardiol Therapeutics (CRDL), Universal Health Services (UHS), Edgewise Therapeutics (EWTX)

    3 Stocks to Keep Watching Closely: Cardiol Therapeutics (CRDL), Universal Health Services (UHS), Edgewise Therapeutics (EWTX)

    Recent changes in investor sentiment suggest a growing preference for precision over broad market exposure, with capital increasingly flowing toward companies that demonstrate tangible growth drivers. This pattern is particularly evident in the biotech sector, where key milestones such as clinical data releases and regulatory decisions often serve as major inflection points for valuation.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is advancing a focused strategy in cardiovascular medicine by targeting inflammatory diseases with limited treatment options and high clinical burden. By concentrating on recurrent pericarditis, the company is positioning its lead therapy, CardiolRx™, as a differentiated solution that addresses both symptoms and underlying inflammation without relying on traditional immunosuppressive approaches.

    Market Momentum

    As of April 16, 2026, CRDL closed at $1.41, down 1.40%, with trading volume (330,690 shares) below its average of 581,219 shares—indicating lighter activity and short-term consolidation. With a market cap of $157.469M, the stock remains within its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.53 continues to suggest significant upside potential, supported by advancing clinical programs.

    Clinical Progress: MAVERIC Trial

    The ongoing Phase III MAVERIC trial represents a pivotal step in Cardiol’s development pathway. This study is designed to evaluate the efficacy of CardiolRx™ in reducing recurrence in patients with recurrent pericarditis. The program builds on strong Phase II results that demonstrated rapid pain reduction and meaningful decreases in inflammation markers, reinforcing confidence in the drug’s potential.

    Commercial Positioning

    CardiolRx™ is being developed as an oral, non-immunosuppressive therapy, offering a safer alternative to existing treatments such as corticosteroids and biologics. This positioning could support long-term use and improve patient adherence, particularly in a condition characterized by recurring episodes.

    Outlook

    With a late-stage trial underway and a clearly defined market opportunity, Cardiol is approaching a key inflection point. Positive Phase III results could significantly enhance its commercial prospects and drive a re-rating of the stock.

    Universal Health Services, Inc (UHS)

    Universal Health Services, Inc (NYSE: UHS) started the day on April 16, 2026, with a price decrease of -0.79% at $178.73. During the day, the stock rose to $182.96 and sunk to $178.54. Taking a more long-term approach, UHS posted a 52-week range of $152.33-$246.32.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 15.93%. Meanwhile, its Annual Earning per share during the time was 15.93%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 8.05%. This publicly-traded company’s shares outstanding now amounts to $53.82 million, simultaneously with a float of $51.22 million. The organization now has a market capitalization sitting at $10.92 billion.

    Edgewise Therapeutics Inc (EWTX)

    As of April 16, 2026, Edgewise Therapeutics Inc (NASDAQ: EWTX) started slowly as it slid -1.72% to $33.12. During the day, the stock rose to $34.07 and sunk to $32.87. Taking a more long-term approach, EWTX posted a 52-week range of $12.15-$34.77.

    In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -36.19%. Meanwhile, its Annual Earning per share during the time was -36.19%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is -28.29%. This publicly-traded company’s shares outstanding now amounts to $106.25 million, simultaneously with a float of $76.79 million. The organization now has a market capitalization sitting at $3.55 billion.

  • Edgewise Therapeutics (EWTX) Stock Jumps After Positive Trial News

    Edgewise Therapeutics (EWTX) Stock Jumps After Positive Trial News

    As of the most recent check, shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX) are up 10.72% in early session, trading at $30.58. Following the publication of positive results from the company’s clinical trial, EWTX shares increased.

    Landmark Results from Phase 2 CANYON Trial

    Edgewise Therapeutics (EWTX) unveiled positive topline results from its Phase 2 CANYON trial evaluating sevasemten in individuals with Becker muscular dystrophy (BMD). The goal of Sevasemten, a novel oral rapid skeletal myosin inhibitor, is to shield muscles from the harm that muscular dystrophies inflict due to contraction.

    Creatine kinase (CK) levels showed notable improvements from baseline, indicating that the experiment met its primary aim. The CANYON trial is noteworthy for being the first to effectively accomplish its primary aim and the biggest interventional study in BMD.

    Secondary endpoints also delivered promising insights. The North Star Ambulatory Assessment (NSAA) revealed a trend towards functional improvement in the sevasemten-treated group. Plasma fast skeletal muscle troponin I (TNNI2), a biomarker of acute skeletal muscle damage, showed significant reductions in comparison to the placebo group.

    Improvement was shown in functional assessments such the 10-meter walk/run, 4-stair climb, and 100-meter timed test. Crucially, compared to those in the placebo group, individuals undergoing therapy had more advanced illness.

    High Tolerance and Continued Engagement

    Sevasemten was well-tolerated across both adult and adolescent patient groups, with no new safety concerns reported. An impressive 99% of eligible participants from CANYON and other sevasemten trials have opted to enroll in MESA, an ongoing open-label extension study. This continued participation underscores confidence in the treatment’s safety and efficacy.

    Hope for a Transformative Therapy

    Becker muscular dystrophy remains an unmet medical need, with no approved therapies currently available. The groundbreaking results from the GRAND CANYON pivotal cohort signal the potential for sevasemten to stabilize functional decline in BMD patients.

    Edgewise Therapeutics plans to complete recruitment for the GRAND CANYON cohort by Q1 2025 and engage regulatory authorities for marketing authorization strategies in the U.S. and Europe. Additionally, EWTX intends to present the full CANYON study findings at an upcoming medical congress.

    Edgewise Therapeutics’ novel approach to treating muscular dystrophies highlights its potential to revolutionize care for Becker muscular dystrophy patients, offering hope for the first approved therapy in this challenging field.

  • Edgewise Therapeutics (EWTX) Experiences Stock Boost After Revealing Successful Trial Data

    Edgewise Therapeutics (EWTX) Experiences Stock Boost After Revealing Successful Trial Data

    The release of top-line data from clinical studies caused Edgewise Therapeutics, Inc. (NASDAQ: EWTX) shares to rise dramatically. During the Thursday session, EWTX stock price increased 54.69% to conclude at $29.50. The favorable results of a clinical study were the driving force behind that surge.

    What Edgewise Therapeutics has shared?

    Edgewise Therapeutics revealed key findings from the Phase 1 trial involving healthy subjects, as well as the single-dose component of the Phase 2 CIRRUS-HCM (obstructive hypertrophic cardiomyopathy) trial.

    EDG-7500 is designed as an oral, selective cardiac sarcomere modulator aimed at reducing early contraction velocity and improving impaired cardiac relaxation linked to HCM. The Phase 1 single ascending dose (SAD) trial had doses ranging from 5 to 300 mg for participants. The multiple ascending dosage (MAD) phase involved the administration of doses ranging from 25 to 100 mg once day for a total of 14 days.

    The absence of any alterations in clinical chemistry, electrocardiograms, or vital signs in either of the two trial segments demonstrated that EDG-7500 was well tolerated. Notably, the MAD portion demonstrated a half-life of approximately 30 hours, with steady-state concentrations achieved after about four days of dosing.

    Efficacy in Patients with Obstructive HCM

    Patients with obstructive HCM were given single doses of 50, 100, or 200 mg of EDG-7500 in the CIRRUS-HCM Part A experiment. There were notable decreases: for individuals taking the 100 and 200 mg dosages, there was a mean reduction in resting left ventricular outflow tract pressure gradient (LVOT-G) of 67% and a mean drop in provoked LVOT-G of 55%. Surprisingly, LVOT gradients below the 30 mmHg threshold were attained by 60% of patients receiving the larger dosages, and the medication had no negative effects on left ventricular ejection fraction (LVEF).

    Future Directions

    Edgewise Therapeutics is moving forward based on these promising results, initiating the 28-day segment of the CIRRUS-HCM trial in both obstructive and non-obstructive HCM patients. The company aims to further evaluate the tolerability, pharmacokinetics, and overall effects on cardiac metrics and biomarkers. Initial results from this segment are expected to be reported in the first quarter of 2025, with high hopes for EDG-7500 to advance the treatment landscape for HCM.